Company Overview and News

 
Genesis Minerals raises $5 million for Ulysses Gold Project

2018-04-13 proactiveinvestors.com.au
Genesis Minerals Ltd (ASX:GMD) has received binding commitments to raise $5 million via a heavily oversubscribed share placement at 3.2 cents each to institutional and sophisticated investors.
Upvote Downvote

 
Genesis Minerals commences drilling at Barimaia gold project in WA

2017-12-07 australianmining.com.au
A 2500-metre reverse circulation drilling program has been launched by Genesis Minerals at the Barimaia gold project in Western Australia.
Upvote Downvote

 
Uranium Equities takes advantage of share spike post lithium anomaly

2017-10-11 proactiveinvestors.com.au
Uranium Equities Ltd's (ASX:UEQ) shares have doubled in value in the past couple of days to $0.011 following a lithium anomaly being identified at its Dundas project in Western Australia.
Upvote Downvote

 
Uranium Equities tops the ASX % Gainers as lithium anomaly identified

2017-10-10 proactiveinvestors.com.au
Uranium Equities Ltd (ASX:UEQ) is the top performer on the ASX this morning, with its shares more than doubling in value to $0.013, following a lithium anomaly being identified at Dundas in Western Australia.
Upvote Downvote

 
Genesis Minerals eyes more gold from mining campaigns at Ulysses

2017-05-08 proactiveinvestors.com.au
Genesis Minerals (ASX:GMD) has unlocked the potential for additional toll-treatment mining campaigns after increasing the resource inventory at the Ulysses Gold Project in Western Australia.
Upvote Downvote

 
Genesis Minerals confirms new gold zone at Ulysses Project

2017-01-25 proactiveinvestors.com.au
The encouraging results are from a follow-up aircore drill program at Genesis’ Ulysses Gold Project near Leonora in Western Australia.
Upvote Downvote

 
Genesis Minerals Ltd begins mining operations at Ulysses Gold Project

2016-10-07 proactiveinvestors.com.au
Genesis Minerals Ltd (ASX:GMD) has commenced open pit mining operations at the Ulysses West open pit, part of the Ulysses Gold Project near Leonora in Western Australia. The commencement of mining marks a significant milestone for Genesis, signalling the all-important transition to production and cash-flow. Mining contractor SMS Innovative Mining Pty Ltd is providing funding to support the project, with an initial subscription of Genesis shares worth $2.
Upvote Downvote

 
Genesis Minerals Ltd begins mining operations at Ulysses Gold Project

2016-10-03 proactiveinvestors.com.au
Genesis Minerals Ltd (ASX:GMD) has commenced open pit mining operations at the Ulysses West open pit, part of the Ulysses Gold Project near Leonora in Western Australia. The commencement of mining marks a significant milestone for Genesis, signalling the all-important transition to production and cash-flow. Mining contractor SMS Innovative Mining Pty Ltd is providing funding to support the project, with an initial subscription of Genesis shares worth $2.
Upvote Downvote

 
Genesis Minerals Ltd eyes imminent start of mining at Ulysses Gold Project

2016-08-09 proactiveinvestors.com.au
Genesis Minerals Ltd (ASX:GMD) is on track to start generating cash flows from the Ulysses Gold Project near Leonora in Western Australia, with mining expected to commence in late September. The company has entered into a mining agreement with contractor SMS Innovative Mining and a toll agreement with Paddington Gold, following the delivery of a positive feasibility study. The feasibility study demonstrated a technically and commercially viable open pit project at Ulysses West, with all in sustaining cost of A$1,060 per ounce of gold with pre-production capex of only $350,000.
Upvote Downvote

 
Genesis Minerals Ltd to reveal contract

2016-08-03 proactiveinvestors.com.au
Genesis Minerals Ltd (ASX:GMD) has been granted a trading halt by the ASX this morning, pending details of a proposed mining operations contract. Genesis recently intersected high-grade gold beneath the historically mined Ulysses Pit, which is located 30 kilometres south of Leonora in Western Australia. The halt will remain in place until the opening of trade on Friday 5th August 2016, or earlier if an announcement is made to the market.
Upvote Downvote

 
Eastern Goldfields Ltd encouraged by Dexy Prospect drilling results

2016-05-26 proactiveinvestors.com.au
Eastern Goldfields Ltd (ASX:EGS) is the owner of the Davyhurst Gold Project in the highly prospective Eastern Goldfields region of Western Australia.
Upvote Downvote

 
Genesis Minerals Ltd signs MOU with Eastern Goldfields for ore treatment

2016-05-25 proactiveinvestors.com.au
Genesis Minerals Ltd (ASX:GMD) will have the gold that produced from its Ulyssess Gold Project processed at the Davyhurst Mill belonging to Eastern Goldfields Ltd (ASX:EGS), after signing an agreement today. The mill is located 135 kilometres away paves the way for GMD to start treating its own ore from the second half of this year. GMD's 100% owned Ulyssess Gold Project produces high grade gold ore.
Upvote Downvote

 
Genesis Minerals Ltd drilling hints at more high grade gold at Ulysses

2016-05-09 proactiveinvestors.com.au
Genesis Minerals Ltd (ASX:GMD) has intersected high-grade gold mineralisation 80 metres down-plunge at the Ulysses Gold Project, located 35 kilometres south of Leonora in the Eastern Goldfields of Western Australia. The best assay from Ulysses West returned 2 metres at 9.0 g/t gold from 153 metres. Importantly, the location of this intersection opens a large prospective area for future resource expansion at Ulysses.
Upvote Downvote

 

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...